Inhibition of PI3K/AKT pathway with a specific inhibitor (LY294002) has been proposed to reduce multi-drug resistance mediated by ABCG2 in cancer stem-like cells and improve GBM chemosensitivity [74]. This evidence concerns the gene AKT1 and glioblastoma.